Rylo Review

What Rylo charges

• Sermorelin: $183/mo — per month as published, billed every three months — the treatment table reads "Sermorelin $183/mo / billed $549 every 3 months", and the FAQ reads "No membership fee, billed once every three months"
• NAD+: $183/mo — per month as published, billed every three months — the treatment table reads "NAD+ $183/mo / billed $549 every 3 months"
• Glutathione: $133/mo — per month as published, billed every three months — the treatment table reads "Glutathione $133/mo / billed $399 every 3 months"
• GHK-Cu: $167/mo — per month as published, billed every three months — the treatment table reads "GHK-Cu $167/mo / billed $499 every 3 months"

The pharmacy is named, and so is the practice

One expandable answer on the home page names the dispensing pharmacy and gives its street address, its city and state, its phone number and its own web address. The same answer names the professional entity that provides the clinical care and says its physicians are licensed in every state.

That is the most complete supply-chain disclosure on this roster. Ten of the thirty-eight sellers compared here name the facility that fills an order, and most of those give a name and nothing else.

A named facility can be looked up. A category cannot. This site records the naming rather than the quality of the facility, because a name is a fact the seller published and a judgment about the facility is not.

The same answer states that the medications are compounded against a valid prescription and are not FDA-approved drug products, and contrasts them with brand-name versions rather than blurring the two.

One table, four compounds, and the full charge beside each rate

The treatment table gives each product a per-month figure and, immediately underneath, the total amount billed and how often. Nothing is left as a bare monthly number.

Four of the six products on that table are compounds this site tracks, sitting across four of the six boards it ranks. The other two are weight-loss medications.

The seller states that the figure does not change with dose or refill and that there is no membership fee on top. A flat rate across doses removes the most common way a peptide price climbs after the first month.

It also says no lab work is required before starting. That is the flip side of no lab work being included, and both are recorded here.

Three months at a time, and a home page that carries the whole disclosure

Every plan bills once a quarter. The smallest purchase available is therefore a quarter of a year, and a reader who wants to try one month cannot.

The company says the charge is fully refundable at any point before the first physician consultation, and that cancelling afterwards takes one button with no fee. Those are two different promises and both are stated plainly.

The treatment pages for each compound return successfully but render nothing readable without JavaScript. The table, the figures and the billing period all live on the home page, which is why every price on this row cites the home page.

That is worth knowing beyond this row: a product page that loads but shows nothing is indistinguishable from a page with no price on it, unless someone checks.

Coverage, qualified

The footer says the service is available in every state, and the pharmacy disclosure repeats it as physicians licensed in every state. The intake's own state selector lists all fifty and no district.

The same sentence then adds that some formulations and fulfillment options vary by state, without saying which formulations or which states. So the fifty-state claim is qualified in a way a reader cannot check before starting an intake.

This row records the fifty-state footprint the seller publishes and puts the qualification in its own list of drawbacks, rather than quietly dropping either half.

Seventeen of the thirty-eight sellers here claim a fifty-state footprint, so the claim itself is unremarkable; the pharmacy naming is what sets this row apart.

How we verified this

• Loaded the home page twice, more than a minute apart, and compared the whole treatment table token by token; the two readings were identical.
• Probed the host with a nonsense path at two different path depths in the same run and confirmed a not-found response at each.
• Loaded all four per-compound routes and found they return successfully while rendering no readable content, which is why the home page is cited as the source for every figure.
• Read the figures in their own markup to confirm they sit in ordinary body copy rather than a hidden or blurred element.
• Recorded the billing period from the table and confirmed it independently in the site's own answer about membership fees.
• Took the pharmacy name, the clinical entity and the operating company from the site's own disclosures rather than from a directory.
• Counted the intake's state selector rather than trusting the fifty-state phrase in the footer.
• Re-counted the pharmacy-naming and all-fifty claims against the current roster rather than reusing earlier figures.